FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Valneva is committed to upholding the highest safety standards and has engaged proactively with health authorities in all territories where IXCHIQ ® is licensed to provide timely information about all ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...

IXCHIQ ® is the world’s first licensed chikungunya vaccine available to address this significant unmet medical need. In addition to Brazil, IXCHIQ ® is approved for the prevention of disease ...

Morningstar brands and products Company Portfolio ...

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review ...

As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommendations for IXCHIQ ® for ...

The European Medicines Agency's (EMA) safety committee has temporarily suspended the use of the vaccine, branded as Ixchiq, in adults aged 65 years and older. The company said it will continue to ...